Group 1 - The core point of the article is that Meinuohua announced the decision not to adjust the conversion price of its convertible bonds during a board meeting held on December 24, 2025 [1] - Meinuohua's revenue composition for the year 2024 is as follows: 96.14% from self-operated pharmaceuticals, 3.52% from trade, and 0.34% from other businesses [1] - As of the report, Meinuohua's market capitalization stands at 4.4 billion yuan [1]